CARM.US Carisma Therapeutics Inc.

Healthcare Biotechnology USA Stocks
0.0004 USD
Close of Nov 13, 2026
0.0001 0.0879
Market cap
USD 16.7K
P/E
0.0x
P/B
114.10x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is CARM.US undervalued?

Graham number

The Graham number of Carisma Therapeutics Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Carisma Therapeutics Inc. fundamental analysis

No fundamental analysis for Carisma Therapeutics Inc. yet.

Carisma Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Carisma Therapeutics Inc.

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, …

Full company profile